References
- American College of Rheumatology subcommittee on osteoarthritis guidelines: recommendations for the management of osteoarthritis of the hip and knee Arthritis Rheum. 2000;43:1905-15.
- Jordan KM, Arden NK, Doherty M, et al: EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-55.
- Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cart 2008;16:137-62
- Conaghan PG, Dickson J, Grant RL, on behalf of the Guideline Development Group. Care and management of osteoarthritis in adults: summary of NICE guidance. Br Med J 2008;336:502-3.
- Strand V, Hochberg MC: Study design and outcome measures in osteoarthritis clinical trials. In Moskowitz RW, Altman RD, Hochberg MC, et al. eds. Osteoarthritis: diagnosis and medical/surgical management, 4th ed. Philadelphia (PA): Wolters Kluwer/Lippincott Williams & Wilkins; 2007. p. 313-25.
- Leeb BF, Schweizer H, Montag K, et al. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11
- McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. J Am Med Assoc 2000;283:1469-75
- Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514-22
- Reichenbach S, Sterchl R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007;146:580-90
- Monfort J, Martel-Pelletier J, Pelletier J-P. Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses. Curr Med Res Opin 2008;24:1303-8
- Laine L, White WB, Rostom A, et al. COX-2 selective inhibitors in the treatment of osteoarthritis. Seminars Arthritis Rheum 2008 Jan 3 [Epub ahead of print].
- Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12
- Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cart 1998;6:39-46
- Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cart 2004;12:269-76
- Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557-60
- Conrozier T. Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6). Presse Med 1998;27:1862-5
- Malaise M, Marcolongo R, Uebelhart D, et al. Efficacy and tolerability of 800 mg chondroitin 4 & 6 sulfate in the treatment of knee osteoarthritis: a randomized, double-blind, multicentre study versus placebo. Litera Rheumatologica 1999;24:31-42
- Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-86
- Reginster JY, Kahan A, Uebelhart D, et al. A two-year prospective, randomized, double-blind, controlled study assessing the effect of chondroitin 4 & 6 sulfate (CS) on the structural progression of knee osteoarthritis: STOPP (Study on Osteoarthritis Progression Prevention). [Presented at 2006 annual scientific meeting of the American College of Rheumatology (abstract L42)] [accessed at: http://www.abstractsonline.com on 12/12/07]
- Piperno M, Hellio le Graverand MP, Conrozier T, et al. Quantitative evaluation of joint space width in femorotibial osteoarthritis: comparison of three radiographic views. Osteoarthritis Cart 1998;6:252-9
- Vignon E, Piperno M, Hellio le Graverand MP, et al. Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon Schuss views. Arthritis Rheum 2003;48:378-84
- Barnhill JG, Fye CL, Williams DW, et al. Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial. J Am Pharm Assoc 2006;46:14-24
- Monfort J, Pelletier J-P, Garcia-Giralt N, et al. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis 2008;67:735-40
- Mazzuca SA, Brandt KD, Katz BP. Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis? Osteoarthritis Cart. 1997;5:217-26
- Brandt KD, Mazzuca SA, Conrozier T, et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J Rheumatol. 2002;29:1308-20
- Conrozier T, Tron AM, Mathieu P, et al. Quantitative assessment of radiographic normal and osteoarthritis hip joint space. Osteoarthritis Cart 1995;3:81-87
- Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New Engl J Med 2006;354:795-808
- Felson DT. Chondroitin for pain in osteoarthritis. Ann Intern Med 2007;146:611-2